Abstract
In the last few decades, novel drug delivery strategies have been a big priority to the formulation scientists. Peptides and proteins have drawn a special attention for their wide scope in the area. Serum albumin, transferrin, recom- binant proteins, virus capsids etc. are used as carrier for drug and biomolecules. Conjugates of polymers with proteins have also shown strong potency in the field of drug delivery. Polyethylene glycol is one of the most successful polymers that has been used extensively to develop protein conjugated formulations. Besides, polyvinyl pyrrolidone, polylactic-co- glycolic acid, N-(2-hydroxypropyl) methacrylamide copolymer, polyglutamic acid have also been investigated. In this re- view, we will highlight on the most recent overview of various advantages, limitations and marketed products of proteins, peptides and protein/peptide-polymer conjugates as drug carriers, such products in clinical trials and their various uses in the field of modern drug delivery. Understanding the key features of these materials and the vigorous research in this field will develop new drug formulations that will combat various types of life-threatening diseases.
Keywords: Conjugates, drug delivery, peptides, proteins, virus nanoparticles.
Protein & Peptide Letters
Title:Peptides, Proteins and Peptide/Protein-Polymer Conjugates as Drug Delivery System
Volume: 21 Issue: 11
Author(s): Biswajit Mukherjee, Swapna D. Karmakar, Chowdhury M. Hossain and Sanchari Bhattacharya
Affiliation:
Keywords: Conjugates, drug delivery, peptides, proteins, virus nanoparticles.
Abstract: In the last few decades, novel drug delivery strategies have been a big priority to the formulation scientists. Peptides and proteins have drawn a special attention for their wide scope in the area. Serum albumin, transferrin, recom- binant proteins, virus capsids etc. are used as carrier for drug and biomolecules. Conjugates of polymers with proteins have also shown strong potency in the field of drug delivery. Polyethylene glycol is one of the most successful polymers that has been used extensively to develop protein conjugated formulations. Besides, polyvinyl pyrrolidone, polylactic-co- glycolic acid, N-(2-hydroxypropyl) methacrylamide copolymer, polyglutamic acid have also been investigated. In this re- view, we will highlight on the most recent overview of various advantages, limitations and marketed products of proteins, peptides and protein/peptide-polymer conjugates as drug carriers, such products in clinical trials and their various uses in the field of modern drug delivery. Understanding the key features of these materials and the vigorous research in this field will develop new drug formulations that will combat various types of life-threatening diseases.
Export Options
About this article
Cite this article as:
Mukherjee Biswajit, Karmakar D. Swapna, Hossain M. Chowdhury and Bhattacharya Sanchari, Peptides, Proteins and Peptide/Protein-Polymer Conjugates as Drug Delivery System, Protein & Peptide Letters 2014; 21 (11) . https://dx.doi.org/10.2174/0929866521666140804160907
DOI https://dx.doi.org/10.2174/0929866521666140804160907 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic:Strategies for Molecular-Based Treatment of Hematological Malignancies (Guest Editor: Per Ole Iversen)]
Current Drug Targets Imatinib and Its Successors – How Modern Chemistry has Changed Drug Development
Current Pharmaceutical Design “Cancer Antigen WT1 Protein-Derived Peptide”-Based Treatment of Cancer -Toward the Further Development
Current Medicinal Chemistry ACE Inhibitors and AII Receptor Antagonists in the Treatment and Prevention of Bone Marrow Transplant Nephropathy
Current Pharmaceutical Design Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas
Current Neuropharmacology Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias
Infectious Disorders - Drug Targets Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials Aim for the Readers! Bromodomains As New Targets Against Chagas’ Disease
Current Medicinal Chemistry Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Modifying Radiation Damage
Current Drug Targets Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs